NCT02031081View on ClinicalTrials.gov

Prucalopride Versus Placebo in Gastroparesis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
GastroparesisDiabetes Mellitus
Interventions
DRUG

Prucalopride

2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days

DRUG

Placebo

2 X 100mg tablets (encapsulated) by mouth once daily for 28 days

Trial Locations (1)

T2N 4Z6

University of Calgary, Calgary

All Listed Sponsors
collaborator

Janssen Inc.

INDUSTRY

lead

University of Calgary

OTHER

NCT02031081 - Prucalopride Versus Placebo in Gastroparesis | Biotech Hunter | Biotech Hunter